Pathological complete response predictor of favorable breast cancer outcome

EORTC Breast cancer trial

2014-04-02

(Press-News.org) Results of EORTC trial 10994 appearing in the Annals of Oncology show that pathological complete response after neoadjuvant chemotherapy is an independent predictive factor of favorable clinical outcomes in all molecular subtypes of breast cancer.

Professor Hervé Bonnefoi of the Institut Bergonié Comprehensive Cancer Centre in Bordeaux and coordinator of this study says, "An analysis such as the EORTC's was needed to consider breast cancer heterogeneity. Until recently, a link between pathological complete response and excellent prognosis had only been shown for some specific subtypes of breast cancer, e.g. triple negative and HER2-positive breast cancers, albeit with conflicting results. We wanted to see if the prognostic implications of pathological complete response, TP53 status, and the treatment administered (taxane or non-taxane) differed among breast cancer subtypes. We performed a landmark and two-step approach multivariate analyses to address these questions."

Patients in the intergroup EORTC 10994/BIG 1-00 phase III trial were randomized to receive either six cycles of anthracycline-based chemotherapy (non-taxane) or three cycles of docetaxel followed by three cycles of eprirubicin/docetaxel (taxane). Researchers used a landmark approach and a two-step multivariate analysis to study the potential effects of three interactions: breast cancer subtype and pathological complete response; breast cancer subtype and TP53 status; breast cancer subtype and treatment arm (i.e., taxane or non-taxane).

A patient was determined to have pathological complete response when no evidence was found of residual invasive cancer (or very few scattered tumor cells only) in the primary tumor and lymph nodes. According to this definition, pathological complete response was observed in 18% of the patients in this trial for whom sufficient data was available (1212 of the 1856 patients randomized).

In the univariate analyses there is no heterogeneity between the Hazard Ratios for pathological complete response in our study across the different subtypes. The prognostic effect of pathological complete response on event-free survival did not differ between breast cancer subtypes in a two-step multivariate analysis and was an independent predictor for better event-free survival (Hazard ratio (HR) = 0.40, P < 0.001 in favor of pathological complete response), distant metastasis-free survival (HR = 0.32, P < 0.001), and overall survival (HR = 0.32, P < 0.001). The findings have been confirmed in the recent FDA meta-analysis.

The treatment administered, i.e., taxane or non-taxane, was an independent predictor only for event-free survival and favored treatment with taxane (HR = 0.73, P = 0.004 ). The interaction between breast cancer subtype and TP53 only approached statistical significance for event-free survival (P = 0.1).

INFORMATION: The EORTC was the legal sponsor of the EORTC 10994/BIG 1-00 phase III trial which was conducted in 38 sites located in nine countries: Belgium, France, Poland, Portugal, Slovenia, Switzerland, Sweden, The Netherlands, and the United Kingdom. This trial was supported the United States National Cancer Institute [grants 2U10 CA11488-31 through 5U10 CA011488-40], La Ligue Contre le Cancer and Cancer Research UK (donations through the EORTC Charitable Trust), the European Union [FP6 Active p53 grant], the Fondation Widmer, and educational grants from Pharmacia and Sanofi-Aventis. Docetaxel (Taxotere®) for this study was provided by Sanofi-Aventis.

ELSE PRESS RELEASES FROM THIS DATE:

'Trans Fat, Regulation, Legislation and Human Health'

2014-04-02

Philadelphia, April 2, 2014 – Clinical Therapeutics features a special report in its March issue focusing on the science and policy leading up to the US Food and Drug Administration's (FDA) preliminary steps toward restricting industrially produced trans fatty acids, or trans fat, at the federal level. "Trans fat is a compelling topic for Clinical Therapeutics to examine, because although it directly impacts human health, it also cues up controversy in multiple disciplines, including economics and politics," said John G. Ryan, Dr.PH., Topic Editor for Endocrinology and ...

Steel-fiber reinforced concrete for conventional construction work as well

2014-04-02

Reinforcing concrete with steel bars is a very common practice in construction. The industrial engineer and researcher Aimar Orbe-Mateo (UPV/EHU-University of the Basque Country) has studied the possible use of a material that is normally used for other applications for these tasks: concrete reinforced with steel fibres.What the study shows is that this material has certain advantages over conventional reinforced concrete; among others, it is less prone to cracking, and it can be used for purposes like the manufacture of cylindrical holding tanks. According to Aimar Orbe-Mateo, ...

Research method integrates meditation, science

2014-04-02

PROVIDENCE, R.I. [Brown University] — Mindfulness is always personal and often spiritual, but the meditation experience does not have to be subjective. Advances in methodology are allowing researchers to integrate mindfulness experiences with brain imaging and neural signal data to form testable hypotheses about the science — and the reported mental health benefits — of the practice. A team of Brown University researchers, led by junior Juan Santoyo, will present their research approach at 2:45 p.m on Saturday, April 5, 2014, at the 12th Annual International Scientific ...

Infants are sensitive to pleasant touch

2014-04-02

Infants show unique physiological and behavioral responses to pleasant touch, which may help to cement the bonds between child and parent and promote early social and physiological development, according to research published in Psychological Science, a journal of the Association for Psychological Science. Previous studies with adults have shown that when the skin is stroked, a specific type of touch receptor is activated in response to a particular stroking velocity, leading to the sensation of "pleasant" touch. Cognitive neuroscientist Merle Fairhurst of the Max Planck ...

Key chocolate ingredients could help prevent obesity, diabetes

2014-04-02

Improved thinking. Decreased appetite. Lowered blood pressure. The potential health benefits of dark chocolate keep piling up, and scientists are now homing in on what ingredients in chocolate might help prevent obesity, as well as type-2 diabetes. They found that one particular type of antioxidant in cocoa prevented laboratory mice from gaining excess weight and lowered their blood sugar levels. The report appears in ACS' Journal of Agricultural & Food Chemistry. Andrew P. Neilson and colleagues explain that cocoa, the basic ingredient of chocolate, is one of the most ...

First peanut genome sequenced

2014-04-02

Athens, Ga. – The International Peanut Genome Initiative—a group of multinational crop geneticists who have been working in tandem for the last several years—has successfully sequenced the peanut's genome. Scott Jackson, director of the University of Georgia Center for Applied Genetic Technologies in the College of Agricultural and Environmental Sciences, serves as chair of the International Peanut Genome Initiative, or IPGI. The new peanut genome sequence will be available to researchers and plant breeders across the globe to aid in the breeding of more productive ...

'3D' test could reduce reliance on animals for testing asthma and allergy medications

2014-04-02

To determine whether new medicines are safe and effective for humans, researchers must first test them in animals, which is costly and time-consuming, as well as ethically challenging. In a study published in ACS' journal Molecular Pharmaceutics, scientists report that they've developed a simple, "3D" laboratory method to test asthma and allergy medications that mimics what happens in the body, which could help reduce the need for animal testing. Amir Ghaemmaghami and colleagues note that respiratory conditions, such as asthma and allergies, are becoming more common. ...

World's oldest weather report could revise Bronze Age chronology

2014-04-02

An inscription on a 3,500-year-old stone block from Egypt may be one of the world's oldest weather reports—and could provide new evidence about the chronology of events in the ancient Middle East. A new translation of a 40-line inscription on the 6-foot-tall calcite block called the Tempest Stela describes rain, darkness and "the sky being in storm without cessation, louder than the cries of the masses." Two scholars at the University of Chicago's Oriental Institute believe the unusual weather patterns described on the slab were the result of a massive volcano explosion ...

JCI Online ahead of print table of contents for April 1, 2014

2014-04-02

NOS1 expression predicts melanoma-dependent immune dysfunction Individuals with cancer often exhibit dysfunctional immune signaling in response to interferon (IFN) stimulation. Furthermore, recent evidence indicates that pSTAT-1 levels, which are indicative of IFN responsiveness, in circulating immune cells are predictive of clinical outcome in melanoma patients. In this issue of the Journal of Clinical Investigation, Qiuzhen Liu and colleagues at Southern Medical University, Guangzhou, China determined that melanoma cells have differing capacity to dampen IFN responses ...

Scientists eager to participate in public discourse on environment

2014-04-02

A survey of more than 500 researchers indicates that scientists have the desire to get more involved in public discussion and policy decisions regarding environmental issues, but have concerns about how their efforts might be perceived. "Scientists debate whether they have a role in advocacy," says Gerald Singh, a PhD student in the Institute for Resources, Environment and Sustainability at UBC, who conducted the survey with his colleagues. "Some feel they need to remain objective and can't engage. Others feel they have a duty to get involved so that decisions are made ...

Pathological complete response predictor of favorable breast cancer outcome

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: